SenesTech
Evolve and ContraPest rodent fertility-control baits.
Something off on this page? Send us feedback.
Profile
Sells Evolve and ContraPest rodent-fertility baits through online, professional, distributor, and municipal channels. Revenue is product sales, with continued consumption needed because the products limit fertility temporarily rather than permanently sterilizing rodents.
Formulates and sells rodent-fertility-control products that reduce reproduction in rats and mice. Evolve Rat and Evolve Mouse are cottonseed-oil soft baits, while ContraPest is a liquid bait for Norway and roof rats; delivery systems include bait stations, starter kits, refills, and a hanging dispenser.
Manufactures at its Arizona facility and sells through direct e-commerce, Amazon, other retailer sites, distributors, pest-management professionals, agricultural and commercial accounts, municipalities, and international distributors. Evolve is the portfolio’s revenue center, and subscriptions support recurring replenishment.
Product availability depends on federal and state authorizations: Evolve uses the minimum-risk pesticide framework and state-by-state approvals, whereas ContraPest requires registrations and label compliance. Production-scale manufacturing is concentrated at one Arizona facility.
Company facts
Key statistics
Year to date −50.7% · Average volume (30d) 115.1K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | −$0.37 | −$0.35 | +4.1% | $601.5K | $770.0K | +28.0% | −22.09% |
| May 12, 2026Q1 FY26 | −$0.33 | −$0.31 | +6.1% | $632.0K | $493.0K | −22.0% | +9.04% |
| Mar 12, 2026Q4 FY25 | −$0.30 | −$0.29 | +3.3% | $776.0K | $421.0K | −45.7% | −15.04% |
| Nov 10, 2025Q3 FY25 | −$0.35 | −$0.28 | +20.0% | $776.0K | $690.0K | −11.1% | −8.05% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $485.0K | $625.0K | $690.0K | $421.0K | $493.0K | $770.0K | |
| Gross profit | $313.0K | $409.0K | $433.0K | $233.0K | $308.0K | $567.0K | |
| Operating income | −$1.7M | −$1.6M | −$1.3M | −$1.9M | −$2.1M | −$1.9M | |
| Net income | −$1.7M | −$1.6M | −$1.3M | −$1.8M | −$2.1M | −$1.8M | |
| Diluted EPS | −$1.28 | −$0.87 | −$0.28 | −$0.35 | −$0.39 | −$0.35 | |
| Gross margin | 64.5% | 65.4% | 62.8% | 55.3% | 62.5% | 73.6% | |
| Operating margin | -342.9% | -258.2% | -195.2% | -446.8% | -429.8% | -241.8% |
Fiscal years (4-quarter sums)FY21 $576.0K · FY22 $1.0M · FY23 $1.2M · FY24 $1.9M · FY25 $2.2M
Balance sheet, Jun 30, 2026Cash & short-term investments $5.1M · Total debt $2.6M · Total assets $9.4M · Shareholders' equity $6.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 5.30M · Float 4.01M · 75.6% free float
A Form 4 total here can count shares the filer formally disclaims — an award voted by proxy, for instance — which the holder's own Schedule 13D/G excludes, so where the two disagree the schedule's smaller figure is used.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Glenbrook Capital Management · 10 percent owner | 1.06M | 19.95% | Form 4 | Aug 10, 2026 |
| PFS Cap Mgt Co | 340.0K | 9.99% | 13G | Aug 12, 2025 |
| Sabby Management, LLC | 218.5K | 4.12% | 13F | May 15, 2026 |
| Renaissance Technologies LLC | 114.0K | 2.15% | 13F | May 14, 2026 |
| Geode Capital Management, LLC | 63.1K | 1.19% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 14, 2026 | Michael Edell | director, officer: Chief Executive Officer | +1,000 | $1.21 |
| Aug 7, 2026 | Glenbrook Capital Management | 10 percent owner | +6,490 | $1.30 |
| Aug 6, 2026 | Glenbrook Capital Management | 10 percent owner | +15,000 | $1.30 |
| Jul 20, 2026 | Glenbrook Capital Management | 10 percent owner | +35,000 | $1.47 |
| Jul 7, 2026 | Michael Edell | director, officer: Chief Executive Officer | +1,000 | $1.43 |
Peers
- Scotts Miracle-Gro
Consumer rodent bait, station, trap, and repellent substitute.
- Neogen
Direct consumer and farm rodenticide, trap, and bait-station substitute.
- Ecolab
Commercial IPM service substitute with bait stations, traps, and monitoring.
- Rollins
Recurring residential and commercial rodent-control service substitute.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| SenesTech | $1.09 | −0.14% | $5.7M | — | — | 2.4 | +23.2% |
| Scotts Miracle-Gro | $60.43 | −0.03% | $3.52B | 52.5 | 13.3 | 1.0 | −1.3% |
| Neogen | $11.66 | 0.00% | $2.54B | — | 39.8 | 2.9 | −0.1% |
| Ecolab | $275.05 | −4.11% | $80.70B | 38.5 | 33.2 | 4.8 | +9.7% |
| Rollins | $36.24 | −0.38% | $17.50B | 33.1 | 30.4 | 4.5 | +7.9% |
| Median | 38.5 | 31.8 | 3.7 | +3.9% |